7-Deoxy-trans-dihydronarciclasine Reduces β-Amyloid and Ameliorates Memory Impairment in a Transgenic Model of Alzheimer’s Disease

  • Yoon Sun Chun
  • Lijun Zhang
  • Huan Li
  • Yurim Park
  • Sungkwon Chung
  • Hyun Ok Yang


The critical pathological feature of Alzheimer’s disease (AD) is the accumulation of β-amyloid (Aβ), the main constituent of amyloid plaques. β-amyloid precursor protein (APP) undergoes amyloidogenic cleavage by β- and γ-secretase generating Aβ at endosomes or non-amyloidogenic processing by α-secretase precluding the production of Aβ at the plasma membrane. Recently, several natural products have been widely researched on the prevention of Aβ accumulation for AD treatment. We previously reported that Lycoris chejuensis K. Tae et S. Ko (CJ), which originated from Jeju Island in Korea, improved the disrupted memory functions and reduced Aβ production in vivo. Here, we further explored the effect of its active component, 7-deoxy-trans-dihydronarciclasine (coded as E144), on Aβ generation and the underlying mechanism. Our results showed that E144 reduced the level of APP, especially its mature form, in HeLa cells overexpressing human APP with the Swedish mutation. Concomitantly, E144 decreased the levels of Aβ, sAPPβ, sAPPα, and C-terminal fragment. In addition, administration of E144 normalized the behavioral deficits in Tg2576 mice, an APP transgenic mouse model of AD. E144 also decreased the Aβ and APP levels in the cerebral cortex of Tg2576 mice. Thus, we propose that E144 could be a potential drug candidate for an anti-amyloid disease-modifying AD therapy.


Alzheimer’s disease β-amyloid precursor protein Cognition-improving effect 7-deoxy-trans-dihydronarciclasine β-amyloid 



Alzheimer’s disease



β-amyloid precursor protein


APP ectodomain fragment β


APP C-terminal fragment β


APP ectodomain fragment α


APP C-terminal fragment α


β-amyloid precursor protein intracellular domain


A Disintegrin and Metalloproteinase


APP carrying the Swedish mutation


immature β-amyloid precursor protein


mature β-amyloid precursor protein






Morris water maze


novel object recognition test


blood-brain barrier


mitogen-activated protein kinase




extracellular signal-regulated kinase


glycogen synthase kinase


Funding Information

This work was funded and supported by the Bio-Synergy Research Project (NRF-2012M3A9C4048793) and the Bio & Medical Technology Development Program (NRF-2015M3A9A5030735) of the Ministry of Science, ICT, and Future Planning through the National Research Foundation, Republic of Korea to HOY. This work was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2016R1D1A1A099) to S.C.

Compliance with Ethical Standards

The animal protocols used in this study were in accordance with the Korea Institute of Science and Technology Animal Care Committee guidelines.

Supplementary material

12035_2018_1023_MOESM1_ESM.docx (2.3 mb)
ESM 1 (DOCX 2344 kb)


  1. 1.
    Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2):741–766CrossRefPubMedGoogle Scholar
  2. 2.
    Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120(4):545–555CrossRefPubMedGoogle Scholar
  3. 3.
    Hardy JA, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356CrossRefPubMedGoogle Scholar
  4. 4.
    Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430(7000):631–639CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bertram L, Tanzi RE (2008) Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9(10):768–778CrossRefPubMedGoogle Scholar
  6. 6.
    Gandy S (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115(5):1121–1129PubMedPubMedCentralGoogle Scholar
  7. 7.
    Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 96(7):3922–3927CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ et al (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273(43):27765–27767CrossRefPubMedGoogle Scholar
  9. 9.
    da Rocha MD, dias Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CAM, Barreiro EJ, Viegas C Jr (2011) The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders ii: Alzheimer’s disease. CNS Neurol Disord Drug Targets 10(2):251–270CrossRefPubMedGoogle Scholar
  10. 10.
    Ko SY, Lee HE, Park SJ, Jeon SJ, Kim B, Gao Q, Jang DS, Ryu JH (2015) Spinosin, a C-Glucosylflavone, from Zizyphus jujuba var. spinosa ameliorates Aβ1-42 oligomer-induced memory impairment in mice. Biomol Ther 23(2):156–164CrossRefGoogle Scholar
  11. 11.
    Howes MJ, Houghton PJ (2003) Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 75(3):513–527CrossRefPubMedGoogle Scholar
  12. 12.
    Guzior N, Wieckowska A, Panek D, Malawska B (2015) Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr Med Chem 22(3):373–404CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kim J, Park Y, Chun YS, Cha JW, Kwon HC, Oh MS, Chung S, Yang HO (2015) Effect of Lycoris chejuensis and its active components on experimental models of Alzheimer’s disease. J Agric Food Chem 63(31):6979–6988CrossRefPubMedGoogle Scholar
  14. 14.
    Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1):47–60CrossRefPubMedGoogle Scholar
  15. 15.
    Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31(1):47–59CrossRefPubMedGoogle Scholar
  16. 16.
    Graebert KS, Popp GM, Kehlw T, Herzog V (1995) Regulated O-glycosylation of the Alzheimer beta-A4 amyloid precursor protein in thyrocytes. Eur J Cell Biol 66(1):39–46PubMedGoogle Scholar
  17. 17.
    Small SA, Gandy S (2006) Sorting through the cell biology of Alzheimer’s disease: intracellular pathways to pathogenesis. Neuron 52(1):15–31CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tomita S, Kirino Y, Suzuki T (1998) Cleavage of Alzheimer’s amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J Biol Chem 273(11):6277–6284CrossRefPubMedGoogle Scholar
  19. 19.
    Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ (2003) Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A 100(11):6382–6387CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17(1):7–30CrossRefPubMedGoogle Scholar
  21. 21.
    Goutte C, Tsunozaki M, Hale VA, Priess JR (2002) APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A 99(2):775–779CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lee SF, Shah S, Li H, Yu C, Han W, Yu G (2002) Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-β precursor protein and notch. J Biol Chem 277(47):45013–45019CrossRefPubMedGoogle Scholar
  23. 23.
    Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M (2007) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28(4):537–547CrossRefPubMedGoogle Scholar
  24. 24.
    Aisen PS, Fau SD, Briand R, Fau BR, Laurin J, Fau LJ, Gervais F, Fau GF et al (2006) A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67(10):1757–1763CrossRefPubMedGoogle Scholar
  25. 25.
    O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185–204CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O’Dowd G, Bowery BJ, Boyce S et al (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90(1):1–13CrossRefPubMedGoogle Scholar
  27. 27.
    Magara F, Müller U, Li ZW, Lipp HP, Weissmann C, Stagljar M, Wolfer DP (1999) Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the beta-amyloid precursor protein. Proc Natl Acad Sci USA 96(8):4656–4661CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Goldstein LS (2012) Axonal transport and neurodegenerative disease: can we see the elephant? Prog Neurobiol 99(3):186–190CrossRefPubMedGoogle Scholar
  29. 29.
    Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P et al (2000) A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5(2):207–216CrossRefPubMedGoogle Scholar
  30. 30.
    Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R (2000) A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 5(2):197–206CrossRefPubMedGoogle Scholar
  31. 31.
    De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Scchrijvers V et al (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of notch intracellular domain. Nature 398(6727):518–522CrossRefPubMedGoogle Scholar
  32. 32.
    Wang X, Zhou X, Li G, Zhang Y, Wu Y, Song W (2017) Modifications and trafficking of APP in the pathogenesis of Alzheimer’s disease. Front Mol Neurosci 10:294CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269(26):17386–17389PubMedGoogle Scholar
  34. 34.
    Bhattacharyya R, Barren C, Kovacs DM (2013) Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J Neurosci 33(27):11169–11183CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    El Ayadi A, Stieren ES, Barral JM, Boehning D (2012) Ubiquilin-1 regulates amyloid precursor protein maturation and degradation by stimulating K63-linked polyubiquitination of lysine 688. Proc Natl Acad Sci U S A 109(33):13416–13421CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Benvegnù S, Wahle T, Dotti CG (2017) E3 ligase mahogunin (MGRN1) influences amyloid precursor protein maturation and secretion. Oncotarget 8(52):89439–89450CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lee CW, Lau KF, Miller CC, Shaw PC (2003) Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines. Neuroreport 14(2):257–260CrossRefPubMedGoogle Scholar
  38. 38.
    Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802(4):396–405CrossRefPubMedGoogle Scholar
  39. 39.
    Saura CA, Valero J (2011) The role of CREB signaling in Alzheimer’s disease and other cognitive disorders. Rev Neurosci 22(2):153–169CrossRefPubMedGoogle Scholar
  40. 40.
    Teich AF, Nicholls RE, Puzzo D, Fiorito J, Purgatorio R, Fa' M, Arancio O (2015) Synaptic therapy in Alzheimer’s disease: a CREB-centric approach. Neurotherapeutics 12(1):29–41CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Brunet A, Datta SR, Greenberg ME (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11(3):297–305CrossRefPubMedGoogle Scholar
  42. 42.
    Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW (2009) The insulin/Akt signaling pathway is targeted by intracellular β-amyloid. Mol Biol Cell 20(5):1533–1544CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9(2):180–186CrossRefPubMedGoogle Scholar
  44. 44.
    Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, Masliah E (2006) Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol 65(2):142–151CrossRefPubMedGoogle Scholar
  45. 45.
    Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57(6):846–851CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Natural Products Research CenterKorea Institute of Science and TechnologyGangneungRepublic of Korea
  2. 2.Department of PhysiologySungkyunkwan University School of MedicineSuwonRepublic of Korea
  3. 3.Division of Bio-Medical Science & Technology, KIST SchoolKorea University of Science and TechnologySeoulRepublic of Korea

Personalised recommendations